key: cord-0944027-rlfnoi24
authors: Monroe, Ian; Schwabe, Michael; Dale, Matthew; Schwabe, Michael; Schenkel, Rachel; Schenarts, Paul
title: The COVID-19 Patient in the Surgical Intensive Care Unit
date: 2021-09-29
journal: Surg Clin North Am
DOI: 10.1016/j.suc.2021.09.015
sha: 2476673c85ded11076f5f962a77a58d9a8e58214
doc_id: 944027
cord_uid: rlfnoi24

COVID-19 continues to rampage around the world. Non-critical care trained physicians may be deployed into the intensive care unit to manage these complex patients. While COVID-19 is primarily a respiratory disease, it is also associated significant pathology in the brain, heart, vasculature, lungs, gastrointestinal tract and kidneys. This chapter provides an overview of COVID-19 using an organ-based, systematic approach.

Coronaviruses, a name derived from their crown-like morphology observed on electron microscope, have been described in literature for over 70 years 1 . They are enveloped, positive single-stranded RNA viruses. These viruses are known to bind to host cells' membrane via a spike protein that facilitates fusion between the virus and host cell. Upon entry into the cell, their genome is replicated and packaged for delivery to other cells 1,2 .

Coronaviruses are known to cause a variety of symptoms. Many are nonspecific, including fever, cough, and generalized fatigue. They are often responsible for upper and lower respiratory tract infections that can vary from mild to severe, with acute hypoxic respiratory failure and acute respiratory distress syndrome (ARDS) being known sequalae of these respiratory infections 1,3,4 .Enteric, central nervous system, renal, cardiac, and hematologic diseases can also develop as a result of coronaviruses 5 . 

As the number of COVID-19 patients has surged, non-critical care trained and even junior physicians have been redeployed from their normal area of practice into the intensive care unit (ICU) to mange patients with this complex disease 9-11 . Organizations such as the Society for Critical Care Medicine12, The American Thoracic Society 13 , and universities 14 have rushed to fill this educational and experience gap with "just in time"

training.

There is a high likelihood that surgical intensivists and non-critical care trained surgeons may be called up to provide critical care for patients who would typically be cared for in a medical intensive care unit. The purpose of this chapter, therefore, is to provide an overview of the pathophysiology, disease manifestations, and treatment options for COVID-19 patients admitted to a surgical ICU. To accomplish this, an organ-based, systematic approach will be utilized. Despite the importance of long-term complications of this infection 15 , the primary focus of this manuscript is critical care.

It is important for the reader to understand that the concepts and strategies presented here are based on the best available current information. Given the rapid evolution of our understanding of this complex disease, up dated recommendations may occur between manuscript submission and publication.

During the COVID-19 epidemic, one of the first known neurological changes was anosmia, leading to a worry in otherwise asymptomatic individuals of an upcoming worse Theories behind the mechanism of SARS-CoV-2 to cause neurological changes is ongoing. Entry into the central nervous system (CNS) may be due to a "trojan horse" theory, where the SARS-CoV-2 virus directly attaches to inflammatory cells such as lymphocytes, granulocytes, and monocytes which all express ACE-2. The virus is then picked up by the lungs and transported throughout the body 19 . The virus is then either deposited into the CNS or target vascular endothelial cells in the CNS causing coagulopathy and vascular endothelial cell dysfunction, with resulting small vessel occlusions and microhemorrhages contributing to subtle neurological and neuropsychiatric changes 20 . Post-mortem studies on cerebral pathology show that the virus can directly cross the blood brain barrier, directly infiltrating astrocytes and J o u r n a l P r e -p r o o f microglia 21 . With the ACE2 receptor widely expressed in brain microvascular and endothelial cells, the SARS-CoV-2 spike protein can directly bind to the receptor and either damage the blood brain barrier or induce a cytokine storm causing inflammation and neuronal damage 22,23 . The subsequent neurological changes may also be secondary due direct retrograde travel of the SARS-CoV-2 virus up the axons to reach the CNS 24 .

The long-term sequalae of COVID-19 infections are needing continued evaluation. With the exaggerated response of the CNS to infection leading to meningitis, encephalitis, meningoencephalitis, continued neurologic manifestations are likely to be associated with a COVID-19 infection if otherwise unexplained 25 . A high proportion of COVID-19 patients in the ICU develop delirium, suggesting microvascular and inflammatory pathologies to cause for neurological changes 26 . The long recovery of anosmic patients points toward long-term neurological changes. The more severely affected patients with strokes, microvascular changes, and brain-damage may have ongoing chronic issues that further studies will elucidate associations with the COVID-19 pandemic.

There is an emerging body of evidence to show that cardiac involvement is not uncommon amongst patients with COVID-19 27-29 . The range of cardiac manifestations of the COVID-19 disease is quite broad and requires a high degree of suspicion in order to diagnose and adequately treat the cardiac manifestations of COVID-19. Here, we will briefly summarize the proposed pathophysiology of COVID-19 cardiac involvement, discuss the J o u r n a l P r e -p r o o f range of cardiac manifestations of the SARS-CoV-2 virus, and briefly discuss potential treatment options relevant to the surgeon caring for COVID-19 patients.

Cardiac Pathophysiology:

As described in the pulmonary section of this publication, the SARS-CoV-2 virus binds to ACE2 receptors in Type 1 & Type 2 pneumocytes as well as other ACE2-expressing cell types, then subsequently enter those ACE2 expressing cells 30 . The ACE2 receptor is found in high amounts in pericytes within adult human hearts, indicating that the heart itself is susceptible to infection by the SARS-CoV-2 virus 31,32 . Indeed, there is evidence to suggest that COVID-19 causes viral myocarditis via direct myocardial cell injury 33 .

Compared with patients who have no underlying comorbidities, patients with cardiovascular disease, diabetes, COPD, HTN, and cancer have been shown to have a higher incidence of severe/fatal COVID-19 disease. It has been shown that patients with conditions that result in high levels of activation of the renin-angiotensin system, such as heart failure, hypertension, and atherosclerosis have higher expression of ACE2 receptors on their cardiac pericytes, possibly pre-disposing them to more severe manifestations of cardiac disease 31,32 .

In addition to direct infection, COVID-19 is known to cause a systemic inflammatory response in severe disease states, which results in high levels of circulating cytokines that cause injury to a host of tissues, including the reticulo-endothelial system as well as at risk for electrolyte disturbances which may trigger arrythmias. Given the interaction of the SARS-CoV-2 virus with the RAAS system, hypokalemia is of particular concern, and is well known to increase susceptibility to a variety of arrythmias 28, 35 .

There have been some studies that have shown an association between COVID-19 and acute coronary syndrome 36,37 . In some case series, patients presented with classic STEMI symptoms without prior COVID-19 symptoms, suggesting that their ACS was not The treatment for ACS in the setting of COVID-19 illness is similar to the algorithm for ACS from any other cause. In the case of STEMI presentation, early cardiac catheter lab activation and coronary angiography is essential. A thorough workup including EKG, cardiac biomarkers, coagulation studies, and possibly echocardiography all may be indicated. In patients with demand-induced cardiac ischemia (type II NSTEMI), treatment should focus on optimizing myocardial oxygen delivery and reducing myocardial oxygen demand by treating the underlying disease process. Referral to centers capable of angiography/PCI is essential for patients with any history of coronary artery disease who have severe COVID-19 features.

Multiple studies which have emerged over the last 18 months have described a link between COVID-19 and new-onset heart failure. Studies have shown that among patients with severe COVID-19, 23%-33% of patients developed new-onset cardiomyopathy, depressed ejection fraction, or cardiogenic shock 40-42 .

In some of the early studies out of Wuhan, China, nearly 50% of the patients who died of COVID-19 developed heart failure 42 . COVID-19 is well known to cause hypoxia and acute lung injury resulting in significant pulmonary hypertension. This can lead to development of right heart failure, and the clinician caring for COVID-19 patient must maintain a high degree of suspicion for developing right ventricular failure.

Workup for potential COVID-19 induced heart failure consists of obtaining a CHF-peptide, troponin biomarkers, transthoracic or transesophageal echocardiography, and in some cases cardiac magnetic resonance imaging (MRI). For patients with suspected right ventricular failure, hemodynamic monitoring via a pulmonary arterial catheter may be indicated.

Treatment for COVID-19-induced heart failure is similar for that of other types of acute heart failure. Limiting preload, particularly in patients with right heart failure, is essential, as well as reducing afterload. Inotropic agents such as epinephrine or dobutamine can be employed to increase the contractile function of the myocardium. In patients with right ventricular failure, particularly due to pulmonary hypertension, milrinone seems to be an effective medication at reducing the pulmonary vasoconstriction while significantly increasing the contractile force of the right ventricle. Inhaled vasodilators such as epoprostenol may also be used to reduce the afterload experienced by the right heart. In severe cases, veno-arterial extracorporeal membranous oxygenation (ECMO) may be utilized to provide both hemodynamic & ventilatory support, however the indications for initiation of VA-ECMO in COVID-19 patients are highly individualized and beyond the scope of this publication.

As described above, COVID-19 can cause injury to the heart via several mechanisms, including hypoxia, exacerbation of underlying coronary artery disease, direct cellular J o u r n a l P r e -p r o o f damage and systemic inflammation 36 . All types of cardiac injury can induce an arrythmia within the cardiac conduction system. Patients with COVID-19 are particularly prone to deviations in serum potassium levels due to the interaction of the SARS-CoV-2 virus with the renin-angiotensin-aldosterone pathway 36 .

Various types of arrhythmias have been seen in COVID-19 patients, including high-grade AV-blocks, supraventricular tachyarrythmias and ventricular tachyarrhythmias 43 . It is imperative that clinicians be mindful of the proclivity for COVID-19 patients to develop arrythmias, particularly in light of the various QT-prolongating medications that may be given to these patients. Cardiac monitoring with telemetry is essential, and regular assessment of the QTc is imperative.

Treatment for these cardiac arrythmias is no different than if they were to arise in a non-COVID-19 patient. Correction of underlying electrolyte derangements, hemodynamic stabilization, and possibly correction of the arrythmia are all warranted.

Studies have shown that COVID-19 tends to cause a hypercoagulable state in affected There is some early evidence to suggest that early anticoagulation is of benefit in COVID-19 patients 47 . Retrospective studies have suggested that use of enoxaparin or other lowmolecular-weight heparins was associated with increased survival in patients with clinical coagulopathy or elevated D-dimer 48 . Recent studies are still mixed with regards to the optimal anticoagulation strategy. One recent study showed no benefit to intermediatedose enoxaparin (1mg/kg daily) compared to standard prophylactic dosing (40mg daily) 49 . Whereas other observational studies have suggested a mortality benefit to treatmentdose anticoagulation, particularly in patients with more severe disease 50 . The European Heart Journal has proposed an algorithmic approach to the level of anticoagulation based on severity of disease, serum biomarkers, level of care, and presence of thromboembolism on point-of-care ultrasound 51 . In general, more severe cases of COVID-19 seem to necessitate higher levels of anticoagulation, however the optimal strategy is still yet to be determined 52,53 .

The Role of Angiotensin-Converting Enzyme 2 (ACE2) in the Lung J o u r n a l P r e -p r o o f ACE2 has been repeatedly demonstrated to be the host receptor of SARS-CoV-2. ACE2

is an essential component of the renin-angiotensin system (RAS). ACE is the enzyme responsible for catalyzing the conversion of angiotensin I to angiotensin II, which promotes the synthesis of aldosterone, vasoconstriction, and increased sodium reabsorption in the kidney's nephrons 2, 54 . Meanwhile, ACE2 inactivates angiotensin II and cleaves it into angiotensin I. Therefore, ACE2 provides a counterbalance to ACE, thus regulating the effect of the RAS system on the body. ACE/ACE2 also play a role in the inflammation process, and a careful balance between pro-inflammatory and antiinflammatory pathways is maintained in healthy patients 54 . In contrast to its proinflammatory counterpart, the anti-inflammatory responsibility of ACE2 provides necessary protection to the lung against injury.

In the lungs, ACE2 is expressed in the alveolar epithelial cells. It has mainly been detected in type II alveolar cells. The role of these cells includes surfactant production, movement of water across the epithelium, and restoration and regeneration of damaged lung alveolar epithelium 55 . The lung's substantial surface area and large concentration of ACE2 contribute to the lung's significant vulnerability to COVID-19 in comparison to other organs.

The interaction between ACE2 and SARS-CoV-2 has been thoroughly investigated.

Research into its binding kinetics show a 10-20x higher receptor preference for SARS-CoV-2 in comparison to SARS-CoV-1, which may provide insight into why the virus is so J o u r n a l P r e -p r o o f easily transmissible 54 . Similar to how other coronaviruses bind to host cells, it is thought the spike protein of SARS-CoV-2 interacts with ACE2, which initiates the release of viral RNA into the epithelial cells 56 .

Hyperinflammation, the cytokine storm and fibrosis:

Once SARS-CoV-2 binds to ACE2, the virus is replicated and cell apoptosis occurs.

Consequently, pro-inflammatory cytokines are released, which upregulate the inflammatory reaction 56, 57 . ACE2 is also downregulated, reducing its anti-inflammatory capabilities in the lung. This local emission of cytokines, including TNF, IL-1, IL-6, IL-8, and MCP-1, is then released into systemic circulation. Homeostasis is progressively lost between pro-inflammatory and anti-inflammatory pathways, which leads to widespread release of cytokines and damage to tissues, including the lung 56,57 . In addition, this cytokine storm also produces a collapse of T-cells, and cellular-mediated adaptive immune response fails to produce meaningful protection for patients with COVID-19 56 . In the lung, ARDS is a common sequela after this widespread cytokine storm.

Downregulation of ACE2 also leads to an increase in angiotensin II. Angiotensin II is proinflammatory and pro-fibrotic, thus contributing to the development of pulmonary fibrosis.

Age is the strongest predictor of severity of COVID-19 disease in patients 54 . One study found that COVID-19 patients below the age of 60 had a 1.38% mortality rate compared to 6.4% for those 60 years in age and older 58 . This may occur for a few reasons. First, J o u r n a l P r e -p r o o f ACE2 expression may increase with age, thus creating a greater susceptibility to COVID-19 in the elderly population 59 . Moreover, it is widely acknowledged that innate and adaptive immune responses weaken with aging, predisposing older populations to a more severe COVID-19 infection.

Evidence supports an association between obesity and higher mortality from COVID-19, with obese patients having 3.4-fold greater odds of developing severe COVID-19 60 .

ACE2 is widely expressed in adipocytes. As a result, when SARS-CoV-2 binds to ACE2, the adipocytes release pro-inflammatory mediators that are then released systemically which affect other organs, including the lungs. Furthermore, it is thought that ACE2 also downregulates pulmonary fibrosis, thus pulmonary fibrosis tends to develop more often in obese patients 60, 61 .

Diabetic patients have a 2.95x higher risk of mortality from COVID-19 in comparison to patients without diabetes, and they are more likely to develop a severe COVID-19 infection, with an odds ratio of 2.58 compared to non-diabetic patients 62 . Diabetes mellitus is known to involve a constant low-grade pro-inflammatory state that consequently compounds inflammatory damage on the lungs. It should be noted, that while this approach is commonly employed, some data suggests that it may also have detrimental effects 73 . 

Indications that were used to initiate VV-ECMO included refractory hypoxia and hypercapnia, or single organ failure. Meanwhile, veno-arterial (VA) ECMO was very rarely used in reported studies. Indications that were used included cardiogenic shock due to cardiac injury 74 . Due to the limited amount of data available, the authors of the meta-analysis recommended caution with utilizing ECMO in the setting of COVID-19 until studies with larger sample sizes are performed to investigate its efficacy.

In ARDS, regardless of etiology, fluid overload can detrimentally affect patients' outcomes, and, consequently, conscientious fluid management is essential. Positive pressure ventilation is known to contribute to pulmonary vasoconstriction, which produces fluid retention and interstitial edema 71, 72 . As a result, restrictive fluid management is recommended, as it is associated with greater ventilator-free days 75 . Unfortunately, fluid J o u r n a l P r e -p r o o f management in patients with ARDS secondary to COVID-19 has not been thoroughly investigated.

Prone positioning has long been utilized for ARDS and acute hypoxic respiratory failure 76.77 . Over the years, when and how to utilize this strategy has been refined 78 .

Prone positioning has now been implemented as a treatment for COVID-19 respiratory sequelae.

Prone positioning is thought to improve oxygenation through several means. First, lung recruitment and perfusion are optimized. Second, the functional lung size is greatly improved. Third, evidenced on echocardiography, right heart strain is significantly reduced by decreasing overall pulmonary resistance 71 .

For awake, non-intubated patients, it has been demonstrated that simply giving these patients supplemental oxygen in the emergency department and placing them in prone position increases oxygen saturation from a median of 80% to 94% 79 . However, studies have shown that upon resupination the increased oxygenation continues in only approximately one-half of patients 80 .Even more, studies have not demonstrated a significant difference in rates of intubation when comparing prone awake patients to supine awake patients, though a delay to intubation has been noted 81, 82 . Also, significant changes in 28-day mortality were not evidenced when comparing proned versus supine patients 82 .

Prone positioning has also been utilized for intubated COVID-19 patients 83 . In ventilated patients, timing of initiating prone positioning is essential. If patients are placed into prone position early in the disease course, then they are less likely to experience in-hospital mortality 84 . Use of early use of the prone position appears to lead to better oxygenation and an earlier pulmonary recovery.

The Gastrointestinal System and Nutrition: GI bleeding does not seem to be increased among COVID patients but a study among New York patients with GI bleeds found that they tended to have significantly poorer outcomes during the pandemic, possibly related to patient's reluctance to present to hospital during an outbreak along with an increased threshold to perform endoscopy in the setting of widespread COVID-19 85 .

A special population to consider in the COVID era is patients with Inflammatory Bowel Disease (IBD). ACE-2 expression has been shown to be elevated during active IBD 95 . An analysis of patients on the SECURE-IBD registry found that of patients with IBD, steroid and mesalamine use have been shown to be associated with higher rates of mortality from COVID-19 with almost 20% of COVID patients who require steroid use for their IBD experiencing ICU admission, mechanical ventilation, or death as part of their clinical course of COVID-19 85 . In contrast, only 2-3% of patients on biologic monotherapy for their IBD experienced these adverse events.

The Liver:

In the setting of patients without preexisting liver disease, COVID-19 associated liver injury tends to be mild in most cases. Elevated AST/ALT has been found to be the most common hepatic manifestation of the disease at an estimated rate of 20-30% 93 ..

However, Hajifathalian et al 97 reported that an association between risk of ICU admission/mortality and the presence of acute liver injury upon admission. Potential mechanisms to explain this process, include drug induced liver injury, direct COVID induced hepatitis/myositis, ACE-2 mediated binding and damage (ACE2 receptors were found to be high in cholangiocytes 98 and though normally were low in hepatocytes their expression has been shown to be inducible by hypoxia and inflammation or preexisting liver disease 99 , hypoxic injury, indirect injury due to systemic inflammation and cytokines, ventilator associated hepatic congestion, and aggravation of preexisting viral hepatitis 100 .

Remdesivir has been found in a large trial (n=1073) to increase liver enzymes 89 Chronic liver disease can also affect COVID treatment options for patients; for example, patients with decompensated cirrhosis are recommended to not receive remdesivir, one of the only antivirals approved to treat COVID-19 85 .

The pandemic has also affected liver transplant programs around the globe; for prospective transplant candidates, it is recommended that transplant be limited to high MELD score patients or those with high risk of decompensation/HCC progression, especially given the decreased number of organs procured during the pandemic 102 . It is also unanimously recommend continuing immunosuppressive therapy in post-liver J o u r n a l P r e -p r o o f transplant patients throughout the COVID pandemic given the increased risk for rejection 102 .

The Pancreas:

Pancreatic acinar cells do express ACE-2 receptors and it was theorized that this could lead to direct viral mediated pancreatic damage but despite several early reports of COVID associated acute pancreatitis, acute pancreatitis seems to be a rare finding in people infected with COVID. One retrospective study of 63,000 COVID patients in Spain found an incidence of only 0.07% of acute pancreatitis amongst these patients 103 .

However, COVID patients were much more likely to be diagnosed with idiopathic pancreatitis vs gallstone or alcoholic pancreatitis (69% compared to 21%), though this was thought to be related to pancreatitis due to widespread multiorgan failure. Many early studies did not use uniform definitions of pancreatitis but instead used elevated serum amylase as an indicator even in the absence of abdominal symptoms 104 

During normal times of health, the vascular endothelium has many roles: immune competence, inflammatory equilibrium, maintaining tight junctional barriers, and aiding in hemodynamic stability. It is well known that the vascular endothelium also plays a significant role in the thrombotic and fibrinolytic pathways. During the COVID-19 epidemic, studies have been able to elucidate many vascular complications associated with infection with this novel virus apart from the known respiratory problems.

Thromboembolic complications have been reported affecting not just the vasculature of the lungs 112 but also the brain 113 , heart 114 , and extremities 115 . The incidence of thrombotic complications in the intensive care unit ranges from 16-69% in the ICU 115 patients in the absence of active bleeding, low platelet counts less than 25,000, and fibrinogen levels less than 0.5 g/L 128 .

Other hematologic issues may also occur in COVID-19 patients. Lymphopenia does develop in more than 50% of patients with COVID-19 infection 129 . The O and Rh-blood groups may be associated with a slightly lower risk for SARS-CoV-2 infection and severe COVID-19 illness. However, the reasons why and the significance of this association have yet to be determined 130 .

Lopinavir-ritonavir is a protease inhibitor and nucleoside analogue combination medication primarily used to treat human immunodeficiency virus (HIV). It was theorized that its dual antiviral nature would be effective in treating COVID-19. However, a systematic risk-benefit analysis of seven peer reviewed journal articles did not demonstrate a clear benefit to using this medication for severe COVID-19 infection.

Dangerous side effects include prolonged QT interval and inhibitor of cytochrome P450 131 .

Chloroquine and hydroxychloroquine are medications that have multiple antiviral mechanisms, including inhibition of viral entry and release of virus into the cell, along with J o u r n a l P r e -p r o o f immunomodularity activities 131 . Despite its rise in popularity in 2020 as a treatment for COVID-19, data is inconclusive in terms of its potential benefit. Dangerous side effects include prolonged QT interval and hypoglycemia [131] [132] [133] . .

Dexamethasone is a corticosteroid that has been utilized to treat COVID-19. A 10-day course has been demonstrated by multiple studies and trials, including the RECOVERY and CoDEX trials, to have a significant decrease in 28-day mortality, number of ventilatorfree days, and incidence of hypoxia 134, 135 . As a result, dexamethasone has become standard of care in the treatment for COVID-19 136 . Despite its benefit in the treatment of COVID-19, dexamethasone is also associated with several complications including glaucoma, hyperglycemia, and hypertension 137 .

Remdesivir is an antiviral nucleoside analogue known to inhibit RNA polymerase that has also been utilized to treat COVID-19. It has been shown to significantly reduce recovery time and has been associated with higher odds of clinical improvement [138] [139] [140] . Side effects are generally mild, but more severe ones include hypotension and cardiac arrythmias.

Convalescent plasma treatment for infectious diseases is characterized by immediate immunity through the administration of passive antibodies 141 benefit and it appears to be safe. Almost all patients that were administered convalescent plasma had symptomatic improvement, and zero mortality was reported 142 . However, a recommendation was made for a large multicenter clinical trial to provide stronger evidence. Recommendations for ideal plasma donors include donors that donate 28 days after the onset of symptoms and had fevers for greater than 3 days 143 . 

Effectiveness of noninvasive ventilation in COVID-19 related-acute respiratory distress syndrome

The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome

Acute Respiratory Distress Syndrome Update, With Coronavirus Disease

Guidelines on the management of acute respiratory distress syndrome

The ARDSnet protocol may be detrimental in COVID-19. Crit Care

Role of extracorporeal membrane oxygenation in COVID-19: A systematic review

Fluid administration and monitoring in ARDS: which management?

Prone positioning in severe acute respiratory distress syndrome

Treatment of ARDS With Prone Positioning

Prone position in ARDS patients: why, when, how and for whom

Early Self-Proning in Awake, Non-intubated Patients in the Emergency Department: A Single ED's Experience During the COVID-19 Pandemic

Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study

COVIDTEAM. Awake Prone Positioning in COVID-19 Hypoxemic Respiratory Failure: Exploratory Findings in a Single-center Retrospective Cohort Study. Acad Emerg Med

Suárez-Sipmann F; COVID-19 Spanish ICU Network. Awake prone positioning does not reduce the risk of intubation in COVID-19 treated with high-flow nasal oxygen therapy: a multicenter, adjusted cohort study

Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure

STOP-COVID Investigators. Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease 2019-Related Respiratory Failure

COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist

Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection. Cell Rep

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19

What GI Physicians Need to Know During COVID-19 Pandemic

ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19

Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges

Considerations in performing endoscopy during the COVID-19 pandemic

Clinical Insights into the Gastrointestinal Manifestations of COVID-19

Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus

COVID-19 extrapulmonary illness -special gastrointestinal and hepatic considerations

Gastrointestinal Manifestations of COVID-19: Impact on Nutrition Practices

Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications

COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract

Pathophysiological mechanisms of liver injury in COVID-19

Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis

COVID-19 in Chronic Liver Disease and Liver Transplantation: A Clinical Review

COVID-19 and acute pancreatitis: examining the causality

Association between acute pancreatitis and COVID-19 infection: What do we know?

Coronavirus disease 2019 and the pancreas

Management of Pancreatic Cancer During COVID-19 Pandemic: To Treat or Not to Treat?

Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology

Zununi Vahed S. Covid-19 and kidney injury: Pathophysiology and molecular mechanisms

The COVID-Kidney Controversy: Can SARS-CoV-2 Cause Direct Renal Infection?

SARS-CoV-2 and the kidney

Management of acute kidney injury in patients with COVID-19

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Coronavirus Disease 2019 (COVID-19) Manifestation as Acute Myocardial Infarction in a Young, Healthy Male. Case Rep Infect Dis

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Thrombosis and Coagulopathy in COVID-19

Thrombosis in COVID-19

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

COVID-19 -A vascular disease

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Coagulation abnormalities and thrombosis in patients with COVID-19

Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Endothelial cell infection and endotheliitis in COVID-19

Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19

Anticoagulation Practice Patterns in COVID-19: A Global Survey

Diagnosing COVID-19 in the Emergency Department: A Scoping Review of Clinical Examinations, Laboratory Tests, Imaging Accuracy, and Biases

Association Between ABO and Rh Blood Groups and SARS-CoV-2 Infection or Severe COVID-19 Illness : A Population-Based Cohort Study

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment

Rethinking the role of hydroxychloroquine in the treatment of COVID-19

QTc prolongation among hydroxychloroquine sulphate-treated COVID-19 patients: An observational study

Acute Respiratory Distress Syndrome Update, With Coronavirus Disease

Dexamethasone vs COVID-19: An experimental study in line with the preliminary findings of a large trial

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial

Pros and cons of corticosteroid therapy for COVID-19 patients

Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: A network meta-analysis

ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 -Final Report

Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19

Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang

Convalescent plasma transfusion for the treatment of COVID-19: Systematic review

Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation